IN2012DN01249A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01249A
IN2012DN01249A IN1249DEN2012A IN2012DN01249A IN 2012DN01249 A IN2012DN01249 A IN 2012DN01249A IN 1249DEN2012 A IN1249DEN2012 A IN 1249DEN2012A IN 2012DN01249 A IN2012DN01249 A IN 2012DN01249A
Authority
IN
India
Prior art keywords
group
alkyl group
haloalkyl
substituted
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Naoki Taka
Masayuki Ohmori
Kyoko Takami
Masayuki Matsushita
Tadakatsu Hayase
Ikumi Hyood
Masami Kochi
Hiroki Nishii
Hirosato Ebiike
Yoshito Nakanishi
Toshiyuki Mio
Lisha Wang
Weili Zhao
Original Assignee
Chugai Pharmaceutical Co Ltd
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43544423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN01249(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Hoffmann La Roche filed Critical Chugai Pharmaceutical Co Ltd
Publication of IN2012DN01249A publication Critical patent/IN2012DN01249A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/0805—Compounds with Si-C or Si-Si linkages comprising only Si, C or H atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IN1249DEN2012 2009-08-07 2010-08-05 IN2012DN01249A (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009184822 2009-08-07
PCT/JP2010/063315 WO2011016528A1 (ja) 2009-08-07 2010-08-05 アミノピラゾール誘導体

Publications (1)

Publication Number Publication Date
IN2012DN01249A true IN2012DN01249A (xx) 2015-05-15

Family

ID=43544423

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1249DEN2012 IN2012DN01249A (xx) 2009-08-07 2010-08-05

Country Status (28)

Country Link
US (2) US8829199B2 (xx)
EP (1) EP2471786B1 (xx)
JP (2) JP5225470B2 (xx)
KR (1) KR101529767B1 (xx)
CN (1) CN102574836B (xx)
AR (1) AR084370A1 (xx)
AU (1) AU2010279930B2 (xx)
BR (1) BR112012008094A2 (xx)
CA (1) CA2770195C (xx)
CL (1) CL2012000324A1 (xx)
CY (1) CY1117142T1 (xx)
DK (1) DK2471786T3 (xx)
ES (1) ES2561659T3 (xx)
HK (1) HK1170236A1 (xx)
HR (1) HRP20151258T1 (xx)
HU (1) HUE028584T2 (xx)
IL (1) IL217912A (xx)
IN (1) IN2012DN01249A (xx)
MX (1) MX2012001653A (xx)
MY (1) MY163531A (xx)
PE (1) PE20120795A1 (xx)
PL (1) PL2471786T3 (xx)
PT (1) PT2471786E (xx)
RU (1) RU2580543C9 (xx)
SI (1) SI2471786T1 (xx)
TW (1) TWI464160B (xx)
WO (1) WO2011016528A1 (xx)
ZA (1) ZA201200895B (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012008094A2 (pt) 2009-08-07 2020-08-18 Chugai Seiyaku Kabushiki Kaisha derivado de aminopirazol, seu uso, composição farmacêutica que o compreende, agentes para inibir a atividade de fgfr e para prevenir ou tratar câncer
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EP2817294B1 (en) * 2012-02-20 2017-12-27 Rhodia Operations Process for production of dfmb derivatives
ME03300B (me) 2012-06-13 2019-07-20 Incyte Holdings Corp Supsтituisana triciklična jedinjenja као inhibiтori fgfr
DK2872491T3 (da) 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
JP6117222B2 (ja) 2012-09-27 2017-04-19 中外製薬株式会社 Ｆｇｆｒ３融合遺伝子およびそれを標的とする医薬
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
CN103224479B (zh) * 2013-04-26 2014-10-15 温州大学 一种2-芳基苯并呋喃类化合物的合成方法
MX362994B (es) * 2013-07-31 2019-03-01 Chugai Pharmaceutical Co Ltd Preparacion farmaceutica que comprende un derivado de aminopirazol.
JP6458023B2 (ja) 2013-10-25 2019-01-23 ブループリント メディシンズ コーポレイション 繊維芽細胞成長因子受容体の阻害剤
CN105814035B (zh) * 2013-12-13 2018-02-02 豪夫迈·罗氏有限公司 布鲁顿氏酪氨酸激酶抑制剂
US9802920B2 (en) 2013-12-13 2017-10-31 Hoffman-La Roche Inc. Inhibitors of bruton's tyrosine kinase
RU2648236C2 (ru) * 2013-12-13 2018-03-23 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
WO2015099127A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
KR20160138494A (ko) 2014-03-31 2016-12-05 데비오팜 인터네셔날 에스 에이 Fgfr 융합물
CA2953004C (en) * 2014-07-08 2023-02-21 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
SG11201700703XA (en) 2014-08-18 2017-03-30 Eisai R&D Man Co Ltd Salt of monocyclic pyridine derivative and crystal thereof
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
US10479780B2 (en) 2015-06-17 2019-11-19 Chugai Seiyaku Kabushiki Kaisha Aminopyrazole derivatives
CA2991846A1 (en) 2015-07-24 2017-02-02 Anne VASLIN-CHESSEX Fgfr expression and susceptibility to an fgfr inhibitor
US10214515B2 (en) 2015-08-20 2019-02-26 Zhejiang Hisun Pharmaceutical Co., Ltd. Substituted pyrazoles as inhibitors of fibroblast growth factor receptor
WO2017157332A1 (zh) * 2016-03-18 2017-09-21 江苏恒瑞医药股份有限公司 芳香酰胺类衍生物、其制备方法及其在医药上的应用
CN110022900A (zh) 2016-09-08 2019-07-16 蓝图药品公司 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SG11202007591RA (en) 2018-03-28 2020-09-29 Eisai R&D Man Co Ltd Therapeutic agent for hepatocellular carcinoma
EA202092649A1 (ru) 2018-05-04 2021-06-21 Инсайт Корпорейшн Соли ингибитора fgfr
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN110092791B (zh) * 2019-05-17 2020-04-03 河南大学 5,6-吲哚并二恶烷类衍生物及其制备方法和应用
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN112358435B (zh) * 2019-10-12 2023-01-10 中国医学科学院医药生物技术研究所 取代芳并杂环类化合物、制备方法和抑制ulk1及抗肿瘤用途
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclyl heterocycles as fgr suppressors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
WO2023107979A1 (en) * 2021-12-08 2023-06-15 Kinnate Biopharma Inc. Treatment of cancer with an fgfr kinase inhibitor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69323212T2 (de) 1992-12-17 1999-05-27 Pfizer Pyrazole mit crf antagonistischer aktivität
NZ507558A (en) 1998-05-05 2003-08-29 F Pyrazole derivatives as P-38 map kinase inhibitors
US6316466B1 (en) * 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
WO2001012600A1 (en) * 1999-08-12 2001-02-22 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
JP2003050945A (ja) 2001-08-06 2003-02-21 Takashi Hashimoto 連動型広告配信システム及び広告配信サーバの動作方法
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
FR2831537B1 (fr) 2001-10-26 2008-02-29 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
FR2854159B1 (fr) 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
TWI452035B (zh) * 2003-06-26 2014-09-11 Novartis Ag 以５員雜環為主之ｐ３８激酶抑制劑
WO2006134318A1 (en) 2005-06-11 2006-12-21 Vernalis R & D Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
EP1968579A1 (en) 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
FR2903406B1 (fr) 2006-07-04 2012-08-10 Aventis Pharma Sa Derives de pyrazolylbenzimidazole,compositions les contenant et utilisation
RU2011106357A (ru) * 2008-07-23 2012-08-27 Ф.Хоффманн-Ля Рош Аг (Ch) Гетероциклические антивирусные соединения
JP2011528686A (ja) * 2008-07-23 2011-11-24 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式抗ウイルス性化合物
BR112012008094A2 (pt) 2009-08-07 2020-08-18 Chugai Seiyaku Kabushiki Kaisha derivado de aminopirazol, seu uso, composição farmacêutica que o compreende, agentes para inibir a atividade de fgfr e para prevenir ou tratar câncer

Also Published As

Publication number Publication date
HRP20151258T1 (hr) 2016-02-26
US20120208811A1 (en) 2012-08-16
PE20120795A1 (es) 2012-07-08
KR20120085736A (ko) 2012-08-01
MX2012001653A (es) 2012-06-19
TWI464160B (zh) 2014-12-11
IL217912A (en) 2015-08-31
RU2580543C2 (ru) 2016-04-10
SI2471786T1 (sl) 2016-03-31
BR112012008094A2 (pt) 2020-08-18
JPWO2011016528A1 (ja) 2013-01-17
JP5225470B2 (ja) 2013-07-03
MY163531A (en) 2017-09-15
CA2770195A1 (en) 2011-02-10
IL217912A0 (en) 2012-03-29
US20140315856A1 (en) 2014-10-23
CL2012000324A1 (es) 2012-09-14
CA2770195C (en) 2015-10-13
AU2010279930A1 (en) 2012-03-08
CN102574836A (zh) 2012-07-11
AU2010279930B2 (en) 2014-09-04
HK1170236A1 (en) 2013-02-22
AR084370A1 (es) 2013-05-15
EP2471786A4 (en) 2013-03-27
EP2471786A1 (en) 2012-07-04
US9102692B2 (en) 2015-08-11
CY1117142T1 (el) 2017-04-05
CN102574836B (zh) 2014-04-16
PT2471786E (pt) 2016-03-04
KR101529767B1 (ko) 2015-06-17
HUE028584T2 (en) 2016-12-28
JP2013144679A (ja) 2013-07-25
DK2471786T3 (en) 2016-01-25
RU2580543C9 (ru) 2016-07-20
RU2012108164A (ru) 2013-09-20
PL2471786T3 (pl) 2016-04-29
JP5732081B2 (ja) 2015-06-10
ES2561659T3 (es) 2016-02-29
EP2471786B1 (en) 2015-11-04
ZA201200895B (en) 2012-11-28
WO2011016528A1 (ja) 2011-02-10
US8829199B2 (en) 2014-09-09
TW201116521A (en) 2011-05-16

Similar Documents

Publication Publication Date Title
IN2012DN01249A (xx)
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
MY160443A (en) Nitrogen-containing heterocyclic compound and agricultural fungicide
MX2012009186A (es) Pirrolidina-2-carboxamidas sustituidas.
TNSN08407A1 (en) Organic compounds
ATE524470T1 (de) Spiroindolinonderivate als antikrebsmittel
ATE495176T1 (de) Spiroindolinon-derivate
MX2010004493A (es) Compuestos de tropano.
CR20120053A (es) Compuestos y metodos inhibidores de jak de pirazolopirimidina
MX344025B (es) Inhibidores de proteínas quinasas.
IN2012DN03129A (xx)
WO2008114817A1 (ja) 新規なアデニン化合物
MX2012003982A (es) Pirrolidinas n-substituidas.
TW200612958A (en) Substituted imidazole derivatives
EP2380874A3 (en) Pleuromutilin derivatives for the treatment of diseases mediated by microbes
TN2009000024A1 (en) Prodrug of cinnamide compound
ATE404536T1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
GB0412769D0 (en) Organic compounds
GB0501964D0 (en) Chemical compounds
PT2197860E (pt) Novos compostos como antagonistas do receptor a1 de adenosina
MY160882A (en) Biocidal composition and method
WO2008003855A3 (fr) Utilisation de 2-benzoyl-imidazopyridines en thérapeutique
EP2578617A4 (en) NYLON CONNECTION
ATE404554T1 (de) Pyrimidinderivate zur verwendung als antikrebsmittel
EP2604261A3 (en) SCCA-1 production inhibitor having a carboxamide derivative and/or a salt thereof as an active ingredient